Nuclear transport: target for therapy

Clin Pharmacol Ther. 2007 Jun;81(6):880-6. doi: 10.1038/sj.clpt.6100141. Epub 2007 Apr 18.

Abstract

Drugs directed at plasma membrane receptors target environment-cell interactions and are the mainstay of clinical pharmacology. Decoding mechanisms that govern intracellular signaling has recently opened new therapeutic avenues for interventions at cytosol-organellar interfaces. The nuclear envelope and nuclear transport machinery have emerged central in the discovery and development of experimental therapeutics capable of modulating cellular genetic programs. Insight into nucleocytoplasmic exchange has unmasked promising anticancer, antiviral, and anti-inflammatory strategies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Active Transport, Cell Nucleus
  • Anti-HIV Agents / metabolism
  • Anti-HIV Agents / pharmacology
  • Anti-Inflammatory Agents / metabolism
  • Anti-Inflammatory Agents / pharmacology
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology
  • Cell Nucleus / metabolism*
  • Cytosol / metabolism
  • Genetic Therapy*
  • Humans
  • Immunosuppressive Agents / metabolism
  • Immunosuppressive Agents / pharmacology
  • Nuclear Pore / metabolism
  • Organelles / metabolism
  • Pharmaceutical Preparations / metabolism*
  • Signal Transduction
  • Transcription Factors / genetics
  • Transcription Factors / metabolism

Substances

  • Anti-HIV Agents
  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Pharmaceutical Preparations
  • Transcription Factors